While sildena l (Viagra ) is widely prescribed for erectile dysfunction, its effect on arterial function is not established. The elastic properties of the aorta, as well as the magnitude and timing of wave re ection, are important factors for ef cient performance of the cardiovascular system and have been identi ed as prognosticators of cardiovascular risk. A total of 24 subjects with coronary artery disease, of whom 14 were hypertensives, aged 69 8 years, were studied in a randomized, placebo-controlled, double-blind, cross-over design. Measurements lasted for 3 h after the sildena l intake (50 mg, p.o.) or placebo. Aortic elastic properties were evaluated with carotid-femoral pulse wave velocity; wave re ection was evaluated with augmentation index and augmented pressure of the aortic pressure waveform. Pulse wave velocity decreased signi cantly (by 0.65 m=s, pˆ0.005), denoting a decrease in aortic stiffness. Augmentation index and augmented pressure decreased signi cantly (by 4.47% absolute and by 4.01 mmHg; p < 0.001 and pˆ0.001, respectively), denoting a decreased effect of wave re ection from the periphery. Aortic pulse pressure decreased signi cantly (by 6.74 mmHg, p < 0.05). An active effect of the drug on aortic wall appears to contribute to the decrease in pulse wave velocity, although other mechanisms such as a decrease of blood pressure and autonomic re exes could also have contributed. The effect of sildena l lasted throughout the study (3 h), being evident 30 min after drug intake. In conclusion, this study shows, for the rst time, that sildena l has a favorable effect on aortic stiffness and wave re ection in patients with coronary artery disease. This nding may have important implications for cardiovascular performance and exercise capacity during intercourse.
Introduction
Erectile dysfunction affects up to 30% of men aged 40-70 years. 1 Sildena l is a highly selective inhibitor of phosphodiesterase type 5, the predominant isoenzyme responsible for the breakdown of cGM P in the corpora cavernosa. By inhibiting cG MP degradation, sildena l allows for improved erectile function and successful sexual intercourse in most men with erectile dysfunction. 2 Erectile dysfunction is particularly common in patients with cardiovascular disease and shares a number of risk factors, including hypertension, older age, diabetes mellitus, hypercholesterolemia and smoking. 1 However, postmarketing data showed temporal association of cardiovascular events with the use of the drug, raising concerns about its safety.
Stiffness of the aorta, as well as the magnitude and timing of wave re ection, are important factors for the performance of the cardiovascular system 3-6 and they [7] [8] [9] have been identi ed, together with their pathophysiological manifestations (i.e. increased systolic pressure, 10, 11 increased pulse pressure [11] [12] [13] [14] [15] and reduced diastolic pressure 11, 14 ) , as prognosticators of cardiovascular risk.
F urthermore, reduction of wave re ection has been associated with improved exercise capacity. 16 Since phosphodiesterase type 5 is widely present throughout the systemic vasculature, 17 we hypothesized that the drug could have a favorable effect on arterial function. In the present study, we investigated the effect of sildena l on arterial stiffness and wave re ection in patients with coronary artery disease.
Methods

Subjects
We studied 24 men (age 69 8 years) with coronary artery disease. In 19 patients, coronary artery disease was de ned angiographically ( ve had single-vessel, 10 had doublevessel, and four had triple-vessel disease). In the remainder, coronary artery disease was de ned clinically and by non-invasive stress testing. F ourteen patients were hypertensive, 15 had hypercholesterolemia, two had diabetes mellitus (one insulin-dependent), and one was a current smoker. The study protocol was approved by the St Vincent's H ospital R esearch Ethics Committee and all subjects gave written informed consent.
Study design
The study was carried out using a randomized, placebocontrolled, double-blind, cross-over design. Each subject was studied in the morning on 2 days separated with a non-xed interval (mean 16 days) after an overnight fast. One day the subjects received sildena l (Viagra , P zer) M edical Professorial Unit, St Vincent's Hospital and Clinic, University of N ew South Wales, Sydney, Australia and the other, placebo. After baseline measurements, the patients took either 50 mg of sildena l or placebo, and all measurements were repeated at 30, 60, 120, 150 and 180 min after drug intake. Cardiovascular medications were discontinued for 24 h before the study. Background medications included ACE inhibitors (14 patients), -blockers (nine patients), calcium channel blockers (six patients), diuretics (six patients) organic nitrates (one patient), angiotensin receptor blockers (one patient), statins (12 patients) and other hypolipidemic agents (two patients).
Evaluation of aortic elastic properties
The pulse travels at a higher velocity in a stiff aorta and vice versa. Pulse wave velocity (PWV) is a well-established index of arterial stiffness and a prognosticator of cardiovascular risk. 7, [18] [19] [20] [21] [22] Carotid-femoral PWV was calculated from measurements of pulse transit time and the distance travelled between two recording sites (PWVˆdistance [meters]=transit time [seconds]), using a validated non-invasive device (Complior , Dupont Medical), which allows on-line pulse wave recording and automatic calculation of PWV. 20
Measurement of wave re ection indices
We used a validated, commercially available system (SphygmoCor ; AtCor Medical, Sydney, Australia) 23, 24 which employs the principle of applanation tonometry 3, 22, [25] [26] [27] [28] and appropriate acquisition and analysis software for non-invasive recording and analysis of the arterial pulse. The technique has been described in detail previously. 3, [22] [23] [24] [25] [26] [27] F rom radial pulse recordings, the central (aortic) arterial pressure was derived with the use of a generalized transfer function which has been shown to give an accurate estimate of the central arterial pressure waveform and its characteristics, 3, 23, 26, 29, 30 and by assuming that the mean pressure in the aorta is the same as the mean pressure in the radial artery since there is practically no change in mean pressure along the arterial tree. 3, 30 Waveforms of radial pressure were calibrated according to sphygmomanometric systolic and diastolic pressure measured in the brachial artery since there is practically no pressure pulse ampli cation between the brachial and the radial artery. 3 The augmentation index (AIx) and augmented pressure (AP) of the central waveform were measured as indices of wave re ection. 3, 22, 24, [26] [27] [28] [29] The pressure waveform recorded at any site of the arterial tree is the sum of the forward traveling waveform generated by pump ejection, and the backward traveling -the 'echo' of the incident wave re ected at peripheral sites. The merging point of the incident and the re ected wave can be identi ed on the pressure waveform as an in ection point. 3 AP is the pressure added to the incident wave by the returning re ected one and represents the pressure boost with which the left ventricle must cope and which is caused by wave re ection. The AIx was de ned as the AP divided by pulse pressure and expressed as a percentage. Larger values of AIx indicate increased wave re ection from the periphery and=or earlier return of the re ected wave as a result of increased PWV (due to increased arterial stiffness), and vice versa.
Statistical analysis
Data are expressed as the mean SEM. Probability values ( p) were derived from two-sided tests, while values less than 0.05 were considered statistically signi cant. Characteristics and resting cardiovascular parameters were compared between the sildena l and placebo sessions using the paired t-test (after controlling for the assumption of normality). Repeated-measures analysis of variance (averaged F) was used to detect statistically signi cant changes in variables within each session separately and between the sildena l and the placebo session (ˆtwo drugs [sildena l vs placebo] seven periods [baseline, 30, 60, 90, 120, 150, and 180 min post-drug]). To take into account the potential effect of mean pressure on PWV changes we adjusted for this covariate by using repeatedmeasures analysis of variance-covariance. Calculations were performed with SPSS software, version 10.0 (Chicago, IL, USA) and SAS software (SAS Institute Inc., Cary, NC, USA).
Results
There were no differences in baseline characteristics between the two sessions (Table 1) . H eart rate increased in the sildena l session (maximum at 90 min, by 2.5 beats per min, p < 0.05), whereas there was no change in the placebo session and no drug interaction. Ejection duration remained unchanged during the study both in the sildena l and placebo sessions and there was no signi cant drug interaction as regards this variable.
Both radial and aortic systolic pressures decreased in the sildena l session ( p < 0.001 for both), whereas they increased in the placebo session ( p < 0.001 for both). There was a signi cant drug interaction for radial ( p < 0.001) and aortic ( p < 0.001) systolic pressure (F igures 1 and 2). Similarly, both radial and aortic diastolic pressures decreased in the sildena l session ( pˆ0.001 for both), whereas they increased in the placebo session ( p < 0.001 for both). F or both radial and aortic diastolic pressure there was a signi cant drug interaction ( p < 0.001 for both; F igures 1 and 2). R adial pulse pressure decreased ( p < 0.05) in the sildena l session and increased ( p < 0.001) in the placebo session; there was no signi cant drug interaction (F igure 1). Aortic pulse pressure decreased ( p < 0.01) in the sildena l session and increased ( p < 0.001) in the placebo session; the drug interaction was signi cant ( p < 0.05; F igure 2).
PWV decreased ( p < 0.05) in the sildena l session and increased ( p < 0.001) in the placebo session. The change in PWV was evident at 30 min and persisted throughout the 3 h of the study. There was signi cant drug interaction as regards PWV ( pˆ0.005; F igure 3). The interaction remained signi cant ( p < 0.05) after adjusting for the effect of mean pressure, indicating that an active effect of the drug on aortic wall contributed in aortic stiffness changes. AIx decreased ( p < 0.05) in the sildena l session and increased ( p < 0.01) in the placebo session; the drug interaction was signi cant ( p < 0.001; F igure 3). The change in AIx was evident at 30 min, reached a nadir at 60 min and persisted throughout the 3 h of the study. AP decreased ( p < 0.005) in the sildena l session and increased ( p < 0.001) in the placebo session; the drug interaction was signi cant ( pˆ0.001; F igure 3).
In the subgroup of hypertensive patients (nˆ14), the ndings regarding all variables were similar to those of the total study population.
Discussion
To the best of our knowledge, this is the rst study to demonstrate the effect of sildena l on aortic elastic properties and wave re ection in patients with coronary artery disease. Oral sildena l decreased aortic stiffness and led to decreased wave re ection, with effects evident 30 min after administration, and lasting for at least 3 h.
M any patients with erectile dysfunction, taking sildenal, have coronary and=or other cardiovascular disease since the two conditions share a number of common risk factors, including hypertension, older age, diabetes mellitus, hypercholesterolemia and smoking. 1 Post-marketing data have shown a temporal association of coronary events with the use of the drug. Although the true association between these events and the effect of the drug is dif cult to de ne, concerns about its use have persisted.
In this study, sildena l produced a bene cial effect on arterial function by reducing aortic stiffness, wave re ection and aortic pulse pressure. In older subjects, such as those studied here, aortic stiffness and early wave re ection increase left ventricular load and myocardial oxygen demands and hinder ventricular function. 3, 4 F urthermore, they compromise coronary blood ow and predispose to ischemia. 3, 5, 27 In addition, by increasing pulse pressure, they increase pulsatile stretch of the arteries leading to mechanical fatigue of their elastic components. Thus, through these mechanisms, stiffening of the aorta and enhanced early wave re ection exert a combined adverse effect on the integrity of the heart and the arteries in older humans. Indeed, increased aortic stiffness, 7,8 enhanced wave re ection, 9 increased systolic pressure, 10,11 pulse pressure [11] [12] [13] [14] [15] (and especially central pulse pressure 15 ), and reduced diastolic pressure, 11, 14 have been identi ed as independent components of cardiovascular risk.
Our study was conducted in the resting state and extrapolations for other situations should be interpreted with caution. H owever, the results of the present study may have implications for exercise capacity, which is an important parameter for successful sexual intercourse. It has been demonstrated that reduction of wave re ection is associated with improved exercise capacity in elderly patients, 16 and studies 31 have shown improvement in exercise capacity with use of sildena l.
Vascular effects of sildena l in humans include dilation of brachial 32 and epicardial coronary arteries, 33 improvement of coronary blood ow reserve in patients with coronary artery disease 34 and improvement in endothelial function. 32, 33, 35 F urthermore, similarly to our ndings, sildena l reduces wave re ection in hypertensive patients. 36, 37 Reduction in wave re ection and part of the reduction in PWV with sildena l can be attributed to dilation of conduit arteries 3 as seen with nitric oxide donors such as nitrates. 38, 39 The mechanisms involved in the effects of sildena l on arterial function can be inferred from its pharmacological action as a vasodilator since PD E5 is present throughout the whole systemic vasculature. 17 An activation of autonomic re exes could also have contributed to the changes observed. The non-signi cant drug interaction on heart rate changes, however, indicates that the contribution of these re exes is probably small.
Although specially designed methodology 19 is needed in order to distinguish whether the effect of a drug on aortic stiffness is due to changes of the intrinsic properties of the aortic wall or due to changes in blood pressure, insights on the mechanism of action of sildena l can be inferred from our study. Indeed, the fact that PWV changes remained signi cant after adjusting for changes in mean pressure indicates that, apart from blood pressure lowering, an active effect of the drug on aortic wall appears to contribute to aortic stiffness changes. N evertheless, the importance and the clinical implications of our ndings are valid irrespective of the mechanism involved.
Our study has some limitations. The results might not be directly extendable to patients with other characteristics and further studies are warranted. In addition, augmentation indices vary with heart rate. H owever, this effect of heart rate on AIx has been quanti ed 40 and since ejection duration remained constant despite an increase in heart rate it can be inferred that, at peak effect, the increase of heart rate by 2.4 beats per minute could have accounted for only 0.97% of the total 4.47% decrease in AIx. Since cardiovascular medications were stopped for 24 h, a small interaction of long-acting drugs with sildena l cannot be excluded.
Conclusion
Sildena l has a bene cial effect on arterial function in patients with coronary artery disease. The effect is explicable on the basis of vascular phosphodiesterase type 5 inhibition. This nding expands our understanding of the overall cardiovascular pro le of sildena l and may have implications for factors affecting cardiovascular performance and exercise capacity during intercourse.
